[
  {
    "ts": null,
    "headline": "Moderna Inc. stock outperforms competitors on strong trading day",
    "summary": "Moderna Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=00ffebb858319e5a6590d1adc14295403096a9068366fb1f9c3c2b528d4ebf36",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733502720,
      "headline": "Moderna Inc. stock outperforms competitors on strong trading day",
      "id": 131891656,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "Moderna Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=00ffebb858319e5a6590d1adc14295403096a9068366fb1f9c3c2b528d4ebf36"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation",
    "summary": "There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...",
    "url": "https://finnhub.io/api/news?id=1068f8813ae8830abc43d1c0d8e3a8c322db80bb6180c81c4725e85b3ef2019c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733494991,
      "headline": "Here's Why We're Watching Moderna's (NASDAQ:MRNA) Cash Burn Situation",
      "id": 131820852,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...",
      "url": "https://finnhub.io/api/news?id=1068f8813ae8830abc43d1c0d8e3a8c322db80bb6180c81c4725e85b3ef2019c"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup",
    "summary": "Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing their consumption of alcohol, according to a new study published recently in the scientific journal JAMA Network Open. Eli Lilly released results this week of a clinical trial comparing its weigh-loss drug Zepbound (LLY) against its rival Novo Nordisk’s Wegovy. Function Health, a lab tests startup, announced this week that its members will now have access to a first-of-its-",
    "url": "https://finnhub.io/api/news?id=7c323d5e438dcf4d5ac772091a41d152490e98280982b37a8c1b0a0cac99fe73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733479200,
      "headline": "Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup",
      "id": 131820853,
      "image": "https://media.zenfs.com/en/quartz.com/b599e532ad5083fcfbc2bc2a20f9b2a9",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing their consumption of alcohol, according to a new study published recently in the scientific journal JAMA Network Open. Eli Lilly released results this week of a clinical trial comparing its weigh-loss drug Zepbound (LLY) against its rival Novo Nordisk’s Wegovy. Function Health, a lab tests startup, announced this week that its members will now have access to a first-of-its-",
      "url": "https://finnhub.io/api/news?id=7c323d5e438dcf4d5ac772091a41d152490e98280982b37a8c1b0a0cac99fe73"
    }
  }
]